12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NVC-422: Phase II/III started

Galderma began the Phase IIb portion of a double-blind, vehicle-controlled, international Phase IIb/III trial to evaluate NVC-422 1.5% topical gel twice and thrice daily for 7 days in >300...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >